Plain-English translation of NCT05837104 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a combination supplement called MagnéVie B6, which contains magnesium and vitamin B6, to see if it can help reduce depression, anxiety, and stress in people with recently diagnosed bipolar I disorder. You would take the medication (or a placebo) three times daily for four weeks, alongside your regular psychiatric care. Previous research suggests this combination may help ease these difficult symptoms during early recovery.
After a first bipolar I diagnosis, many people struggle with persistent depression and anxiety that increase the risk of relapse and disability. This treatment targets the biological processes involved in bipolar disorder and aims to provide relief from these challenging symptoms in the early stages of illness.
You likely qualify if…
You likely don't qualify if…
You would visit the research site to be screened and enrolled, then take either the mineral supplement or a placebo tablet three times daily for four weeks while continuing your regular psychiatric treatment. During the study, you may have visits for check-ins, mood assessments, and possibly a brain scan called magnetic resonance spectroscopy to measure magnesium levels and energy metabolism in your brain. The entire study lasts about four weeks from start to finish.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Mclean Hospital
Enrollment target
~40 participants
Started
December 2023
Primary completion
October 2026
Age range
18 Years – 50 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kyle Cuklanz, B.S.
Mclean Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.